Moderna completes enrollment in its large COVID-19 vaccine study

Company says, over 25,650 participants have so far received their second shot of the vaccine candidate

Tribune Web Desk

Updated At : 01:05 AM Oct 23, 2020 IST

Unlock Exclusive Insights with The Tribune Premium

Take your experience further with Premium access. Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits

Yearly Premium ₹999 ₹349/Year

Yearly Premium $49 $24.99/Year

London, October 22

Moderna Inc said on Thursday it had completed enrolling 30,000 participants in a late-stage study testing its experimental coronavirus vaccine.

Over 25,650 participants have so far received their second shot of the vaccine candidate, mRNA-1273, the company said.

Moderna said its study includes more than 11,000 participants from minority communities in the US, representing 37 per cent of the study population. Reuters

The Tribune, now published from Chandigarh, started publication on February 2, 1881, in Lahore (now in Pakistan). It was started by Sardar Dyal Singh Majithia, a public-spirited philanthropist, and is run by a trust comprising five eminent persons as trustees.

The Tribune, the largest selling English daily in North India, publishes news and views without any bias or prejudice of any kind. Restraint and moderation, rather than agitational language and partisanship, are the hallmarks of the newspaper. It is an independent newspaper in the real sense of the term.

The Tribune has two sister publications, Punjabi Tribune (in Punjabi) and Dainik Tribune (in Hindi).

Remembering Sardar Dyal Singh Majithia

Designed and developed by : SORTD

Unlock Exclusive Insights with The Tribune Premium

Suggested Articles